-
Endpoints News3 weeks ago
Verily raises $300M, sheds Alphabet’s majority control
Verily has raised $300 million in new, outside funding that ends parent company Alphabet’s controlling position in the healthcare innovation company, Endpoints News has learned exclusively....
-
Endpoints News3 weeks ago
TerraPower’s $450M radioisotope factory; Lilly’s $126M Japan budget
TerraPower Isotopes, a subsidiary of founder Bill Gates’ nuclear company TerraPower, is building an actinium-225 factory in Philadelphia. Production will start in 2029. TerraPower Isotopes said...
-
Fierce Biotech3 weeks ago
Chutes & Ladders—Eric Topol boards Flagship as advisor
Renowned cardiologist Eric Topol, M.D., is setting sail with Flagship Pioneering as an academic advisor for the firm’s Preemptive Health and Medicine Initiative. Topol is director...
-
AI & Machine Learning in Biotechnology3 weeks agoSTAT+: Democrats prepare for health care overhaul
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
Endpoints News3 weeks ago
CSL says its hemophilia B gene therapy is out of stock
CSL Behring disclosed a “temporary global stockout” of its gene therapy for hemophilia B that it says could delay treatment for some patients. In a letter...
-
AI & Machine Learning in Biotechnology3 weeks agoSTAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing it with a new catalyst as it tries...
-
BioPharma Dive – AI / Data3 weeks agoLilly’s three-pronged obesity drug hits goal in large diabetes trial
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful...
-
Fierce Biotech3 weeks ago
Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin
Embecta has agreed to pay 100 million pounds sterling upfront for the company, or about $134.3 million, plus another 50 million pounds in sales milestones.
-
BioPharma Dive – AI / Data3 weeks agoPfizer aims for wider use of PARP drug in prostate cancer with new data
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should justify use in earlier lines...
-
Biotech Industry Intelligence3 weeks ago
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
